Core Viewpoint - Junshi Bioscience has reported significant growth in its core product, Toripalimab, with a domestic sales revenue of 1.501 billion yuan in 2024, representing a year-on-year increase of approximately 66% [1][2]. Group 1: Sales Performance - The domestic revenue for Toripalimab in the first quarter of 2025 was approximately 447 million yuan, showing a year-on-year growth of about 45.72% [1][2]. - Toripalimab has received approval for 12 indications in mainland China, with 10 of these included in the national medical insurance catalog, enhancing its market accessibility [2][3]. Group 2: R&D Pipeline - The company has expanded its innovative research and development to cover five major therapeutic areas, including oncology, autoimmune diseases, chronic metabolic diseases, neurological diseases, and infectious diseases [3][4]. - Currently, the company has four commercialized drugs and nearly 30 drugs in clinical trials, with over 20 drugs in preclinical development [3][4]. Group 3: Clinical Trials and Internationalization - The PD-1/VEGF bispecific antibody is in Phase II clinical trials, while the anti-BTLA monoclonal antibody combined with Toripalimab is undergoing Phase III clinical research with over 300 patients enrolled [2][5]. - The company aims to achieve globalization through organic growth and strategic partnerships, enhancing its overseas clinical team and pursuing international multi-center clinical trials [5][6].
君实生物接待74家机构调研,包括万家基金、中信资管、华安基金等